Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
…
continue reading
CME credits: 0.25 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/no-patient-left-behind-advancing-ckd-associated-pruritus-care/26637/ Patients with chronic kidney disease-associated pruritus (CKD-aP) often face delays in diagnosis and treatment, as well as potential side effects from some prescribed medicines. Tun…
…
continue reading
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-in-myasthenia-gravis-crafting-personalized-treatment-strategies/32244/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term…
…
continue reading
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-science-behind-fcrn-antagonists-a-deep-dive-into-their-mechanism-of-action/32241/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but…
…
continue reading
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-symptoms-the-true-impact-of-gmg-on-patients-lives/32235/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them m…
…
continue reading
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-in-mg-their-role-in-diagnosis-and-treatment/32239/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them man…
…
continue reading
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-gmg-navigating-current-tools-and-approaches/32238/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many de…
…
continue reading
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/life-threatening-events-understanding-and-preventing-myasthenic-crisis/32237/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring w…
…
continue reading
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-fcrn-therapy-addressing-and-reducing-adverse-reactions/32243/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with t…
…
continue reading
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/balancing-risk-and-benefit-traditional-mg-treatments-and-medications-to-avoid/32240/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but …
…
continue reading
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/understanding-disease-progression-the-shift-from-ocular-to-generalized-mg/32236/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but brin…
…
continue reading
CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/fcrn-antagonists-in-myasthenia-gravis-a-new-era-in-targeted-therapy/32242/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with…
…
continue reading
CME credits: 0.25 Valid until: 15-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-cycle-addressing-hyperkalemia-in-ckd-and-heart-failure-to-optimize-raasi-therapy/26746/ Patients with CKD or heart failure face the risk of developing hyperkalemia, and healthcare providers often experience clinical inertia in their trea…
…
continue reading
CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pharmacotherapy-in-obesity-current-and-emerging-options/29932/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having suffici…
…
continue reading
CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/breaking-the-bias-addressing-stigma-in-obesity-care/29931/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient,…
…
continue reading
CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-power-of-teamwork-multidisciplinary-obesity-care/29934/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient…
…
continue reading
CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/personalized-obesity-management-a-comprehensive-approach/29933/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having suffic…
…
continue reading
CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-power-of-shared-decision-making-in-obesity-care/29935/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient,…
…
continue reading
CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnosing-obesity-beyond-bmi/29930/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategie…
…
continue reading
CME credits: 1.25 Valid until: 31-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/a-global-health-crisis/29928/ Obesity is a chronic, progressive disease, and in 2022, it affected nearly half of all adults worldwide, making it a global health crisis. This reinforces the importance of having sufficient, appropriate strategies avail…
…
continue reading
CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-evolving-treatment-landscape-for-mbc-emerging-therapies/29831/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines ar…
…
continue reading

1
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-implications-of-current-guidelines-on-first-line-immunotherapy-and-parp-inhibitors-for-tnbc/29827/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics.…
…
continue reading
CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/immunotherapy-for-tnbc-in-the-perioperative-setting-clinical-evidence-and-considerations/29825/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Cl…
…
continue reading

1
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/biomarker-directed-approaches-for-frontline-treatment-of-advanced-gastricgej-cancers-the-evidence/29846/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. T…
…
continue reading
CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-for-the-definition-and-treatment-of-her2-low-breast-cancer/29829/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinic…
…
continue reading
CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/current-guideline-recommendations-for-biomarker-based-second-line-treatment-of-mcrc/29851/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines …
…
continue reading
CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-viewpoint-optimizing-breast-cancer-treatment/29832/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regula…
…
continue reading
CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/immunotherapy-based-approaches-for-first-line-treatment-of-advanced-hcc-the-evidence/29849/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines…
…
continue reading
CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/management-of-hr-her2-high-risk-ebc/29833/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to p…
…
continue reading
CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/novel-neoadjuvant-and-adjuvant-immunotherapy-strategies-for-gi-malignancies-the-evidence/29854/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidel…
…
continue reading

1
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/expert-opinion-key-insights-on-gi-malignanciesintegrating-nccn-clinical-practice-guidelines-into-practice/29855/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment sele…
…
continue reading
CME credits: 0.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/unmasking-igan-from-suspicion-to-timely-diagnosis/26629/ Because renal biopsy is required for diagnosis, providers must be able to identify the histopathological characteristics of IgA nephropathy and implement a systemic diagnostic approach. In addi…
…
continue reading
CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-treatment-approaches-for-ebc/29830/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guidelines are regularly updated to…
…
continue reading
CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-her2-directed-therapy-for-second-line-treatment-of-her2-metastatic-breast-cancer/29828/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCC…
…
continue reading

1
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-biomarker-driven-therapies-in-the-second-line-treatment-of-advanced-gastricgej-cancers-what-do-the-data-say/29847/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for …
…
continue reading
CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/first-line-treatment-of-msi-hdmmr-mcrc-the-role-of-immunotherapy/29850/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly updat…
…
continue reading
CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/adjuvant-treatments-for-hrher2-ebc-the-role-of-cdk46-and-parp-inhibitors/29826/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice …
…
continue reading
CME credits: 1.50 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/management-of-her2-low-mbc-following-first-line-disease-progression/29834/ Treatment decision-making in breast cancer is complex and incorporates several factors including disease- and patient-related characteristics. The NCCN Clinical Practice Guide…
…
continue reading

1
First-Line Advanced Gastric Cancer: Best Practices for Biomarker-Directed Treatment Approaches—A Case Study
CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/first-line-advanced-gastric-cancer-best-practices-for-biomarker-directed-treatment-approachesa-case-study/29848/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment sele…
…
continue reading
CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/applying-current-guidelines-in-the-first-line-treatment-of-msi-hdmmr-mcrca-case-discussion/29852/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guid…
…
continue reading
CME credits: 1.25 Valid until: 30-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-directions-in-biomarker-directed-therapy-for-gi-malignancies/29853/ The NCCN Clinical Practice Guidelines are crucial tool in the treatment of cancer and provide detailed recommendations for treatment selection. The guidelines are regularly …
…
continue reading
CME credits: 0.50 Valid until: 23-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/time-out-a-case-based-deep-dive-into-the-challenges-of-aria-management/26588/ Amyloid-related imaging abnormalities (ARIA) can represent a significant clinical challenge in the acute management of some patients with Alzheimer's disease receiving anti…
…
continue reading
CME credits: 0.75 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/effective-monitoring-and-management-of-adverse-effects-in-metastatic-escc/29792/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoin…
…
continue reading
CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/risk-assessment-in-pulmonary-hypertension-practice-trends-and-updates/28867/ Hear about the latest updates in risk assessment and find out how you can accurately use risk stratification to categorize patients in a timely manner to improve both their …
…
continue reading
CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-management-practice-trends-and-updates/28868/ The landscape of medication management for patients with pulmonary hypertension (PH) has significantly changed with the introduction of combination therapy and recent trial data. Th…
…
continue reading
CME credits: 0.75 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/distinguishing-between-anti-pd-1-agents-in-escc-combination-therapies/29790/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint in…
…
continue reading
CME credits: 0.75 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-importance-of-pd-l1-testing-shaping-the-future-of-treatment-in-escc/29791/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint …
…
continue reading
CME credits: 1.00 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/pulmonary-hypertension-comorbidities-with-pah-and-group-2-ph/28869/ Providers face challenges when it comes to pulmonary hypertension (PH), especially when distinguishing between PAH with comorbidities and group 2 PH. In addition, PH resulting from l…
…
continue reading
CME credits: 0.50 Valid until: 19-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/an-overview-of-aria-a-multidisciplinary-crash-course-for-baseline-clinical-needs/26587/ Amyloid-related imaging abnormalities (ARIA) can pose a significant challenge in the management of Alzheimer's disease, necessitating a collaborative, interdiscip…
…
continue reading
CME credits: 0.25 Valid until: 16-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/copd-care-partnership-between-primary-care-and-pulmonary-providers/26927/ Primary care providers can play a pivotal role in a patient’s COPD diagnosis by looking out for signs and symptoms and referring patients to pulmonologists when appropriate. Th…
…
continue reading
CME credits: 0.25 Valid until: 16-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/finally-i-can-take-a-break-from-my-itch-optimizing-ckd-ap-treatment/26639/ Patients with advanced kidney disease undergoing dialysis are frequently affected by the symptom clusters of chronic kidney disease-associated pruritus, or CKD-aP. These sympt…
…
continue reading